Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, on Tuesday reported financial results for the third quarter of 2023.
Revenues came in at $7.05 billion in the September quarter, compared to $7.04 billion in the corresponding period of 2022. For fiscal 2023, the company expects product revenues to be in the range of $26.7 billion to $26.9 billion.
Adjusted net income was $2.29 per share in the third quarter, vs. $1.90 per share in the prior-year period. The company reported an unadjusted profit of $2.18 billion or $1.75 per share for the quarter, compared to $1.79 billion or $1.43 per share in Q3 2022.
The post Gilead Sciences reports Q3 earnings. Here’s everything you need to know first appeared on AlphaStreet.
(The post is shared from syndication feed, it is not edited by Analyzing Market Team.)